MONTPELLIER CANCER CENTER Post-doctoral position in cancer

MONTPELLIER CANCER CENTER
Post-doctoral position in cancer biology to study
metabolic reprogramming during melanoma progression
The Le Cam's laboratory in Montpellier Cancer Center (IRCM, www.ircm.fr) is looking for a
postdoctoral research fellow to develop a project on metabolic reprogramming of melanoma
cells and its role in tumor invasiveness. The project will focus on the role of important
components of the p53 pathway in the metabolic reprogramming of melanoma cells, using
genetically engineered mouse models and human melanoma samples. The candidate will also
study tumor heterogeneity from the metabolic point of view, using cutting edge technologies
including Mass-Spectrometry tissue imaging techniques, single cell tracing and analyses, tissue
imaging and 3D reconstruction approaches.
As a start, the successful candidate will be appointed with a 2 years felllowship from the Labex
Epigenmed consortium (www.epigenmed.fr).
Preferred Qualifications:
Some prior experience in mouse genetics and/or mass spectrometry analyses are preferred
For more information about this position and the project,
please contact [email protected]
Research Summary of the laboratory
Our team is interested in molecular circuitries implicated in cellular senescence and stem cell
function, and how deregulation of these biological processes affects organismal aging and
tumorigenesis. Our project aims at characterizing new regulatory mechanisms of the p53
pathway, including those implicating the multifunctional protein E4F1 and the MDM2
oncoprotein. Both E4F1 and Mdm2 are E3 ligases that regulate p53 at the post-translational
level. In the past years, we also identified atypical functions of those important regulators of the
p53 pathway and found that they regulate various metabolic pathways. Using genetically
engineered mouse models and metabolomic approaches, we are characterizing the impact of
those complex metabolic networks in stem cell maintenance and normal tissue homeostasis. In
collaboration with clinicians and pathologists, we also investigate the relevance of these new
regulatory mechanisms of the p53 pathway to human tumorigenesis, with a particular interest in
melanoma and liposarcoma.
Bibliography from the host laboratory:
• Rodier G.*, et al. (2015). The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial
functions. Cell Rep. Apr 14;11(2):220-33.
• Hatchi E. et al. (2011) E4F1 deficiency results in oxidative stress-mediated cell death of leukemic cells. J. Exp. Med.
Jul 4;208(7):1403-17.
• Lacroix M. et al. (2010). Transcription factor E4F1 is essential for epidermal stem cell maintenance and skin
homeostasis. Proc Natl Acad Sci U S A. Dec 7; 107(49): 21076-81
• Le Cam L. et al. (2006). E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of
degradation. Cell. Nov17;127(4):775-88.
L
LauLauren
Institut de Recherche en Cancérologie, INSERM U1194, 208 rue des apothicaires 34298 Montpellier Cedex 5 – France
www.ircm.fr